Catalyst Brief

← Calendar

Readoutin 75d

Novartis Pharmaceuticals — Remibrutinib

Phase 3 primary completion: A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines.

Date
Feb 2027
Type
Readout
Indication
Chronic Spontaneous Urticaria (CSU)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Novartis Pharmaceuticals

  1. May2027
  2. May2027
  3. Apr2027
  4. Mar2027
  5. Feb2027
    Readoutin 75d
    Novartis Pharmaceuticals — everolimus
    Phase 3 primary completion: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment.